← The record

Triglycerides, Long Chain; Triglycerides, Medium Chain

Recommended MetabolicRestrictedNot applicable line

Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency (long chain); dietary management of conditions requiring medium chain triglycerides including chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, and fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).

1
Submissions
1 resub
2017–17
On the record
ICER range
Not modelled
Cost basis

Access path

1 submission · public record
  1. Mar 2017
    Recommended
  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC noted the change to the listings processed by the secretariat. 3PSD · Mar 2017

Cost-effectiveness

not-modelled — minor submission for formulation/product-form change with no economic evaluation

Decision context

PopulationPatients with intractable seizures requiring ketogenic diet; glucose transport protein defect; pyruvate dehydrogenase deficiency (long chain); chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, or fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2017 Recommended Other

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC specifies particular medical conditions (intractable seizures, genetic disorders, specific malabsorption causes) versus broad TGA label covering all foods for special medical purposes.